Genitourinary cancer is the term used to describe cancers that affect the organs of genitourinary system which includes the kidneys, bladder, ureters, urethra, male genitalia and prostate. Of note, potentially fatal neoplasms of the prostate, bladder and kidney are some of the world’s most commonly diagnosed cancers.
A number of genetic and environmental factors may put an individual at higher risk of developing genitourinary cancer. These risk factors may be modifiable, such as smoking, or non-modifiable such as age. Infection with specific pathogens, like human papillomavirus (HPV) may also increase risk of certain genitourinary cancers.
Symptoms vary significantly between genitourinary cancers, but early detection generally results in improved prognosis and therefore raising patient awareness of what to look out for is key to improving disease outcomes.
Treatment options available to patients with genitourinary cancers include surgery, radiation therapy, chemotherapy and targeted therapies, which are often used in combination and are selected based on a range of patient and disease specific factors.
To find out more about one of the most common types of genitourinary cancer, visit our dedicated Prostate Cancer Learning Zone where you will find information on the symptoms, diagnosis and treatment of this condition.
Featured Learning Zones
Related news and insights
Merck Inc., known as MSD outside of the United States and Canada, announced results from the Phase III AMBASSADOR (A031501)/KEYNOTE-123 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, for the adjuvant treatment of high-risk patients with localized muscle-invasive urothelial carcinoma (MIUC) and locally advanced resectable urothelial carcinoma.
Astellas Pharma Inc. and Pfizer Inc. announced that on January 26 , 2024 the European Medicines Agency (EMA) validated for review a Type II variation application for Padcev (enfortumab vedotin) with Keytruda (pembrolizumab) as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
Exelixis, Inc. announced detailed results from CONTACT-02, a phase III pivotal study evaluating cabozantinib (Cabometyx) in combination with atezolizumab compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable extra-pelvic soft tissue disease who have progressed on one prior NHT